Cargando…
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
Autores principales: | Lebeaux, David, Revest, Matthieu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332914/ https://www.ncbi.nlm.nih.gov/pubmed/32629139 http://dx.doi.org/10.1016/j.tmaid.2020.101819 |
Ejemplares similares
-
Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
por: Bonny, Aimé, et al.
Publicado: (2020) -
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
por: Million, Matthieu, et al.
Publicado: (2020) -
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
por: Lagier, Jean-Christophe, et al.
Publicado: (2020) -
Hydroxychloroquine and azithromycin as a treatment of COVID-19
por: Fanin, Alice, et al.
Publicado: (2020) -
Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis
por: Lagier, Jean-Christophe, et al.
Publicado: (2022)